What were the primary drivers behind the revenue decline in the third quarter of 2001?

The primary drivers for the revenue decline were market downturns in the telecommunications and semiconductor industries, which significantly impacted sales in the Optical Technologies and Measurement & Control segments. Additionally, divestitures of certain businesses also contributed to the overall decrease in reported revenue.

How did restructuring and unusual costs affect the company's profitability?

Restructuring and other unusual costs, amounting to $9.6 million in the third quarter of 2001, directly reduced operating income. These costs were associated with workforce reductions, discontinuing product lines, and consolidating facilities as part of a plan initiated in the second quarter of 2001 to streamline operations and reduce expenses in response to market conditions.

What is the status of the company's discontinued operations, and how are they being managed?

The company has actively managed its discontinued operations, including the sale of its power generation business components in June and July 2001, which resulted in a gain. Furthermore, the company is preparing for a spinoff of its Viasys Healthcare subsidiary, expected to occur in November 2001. The company also holds a significant investment in Thoratec Corporation, received from the sale of Thermo Cardiosystems, the value of which is subject to market fluctuations and could materially affect the ultimate proceeds from discontinued operations.

What is the company's outlook regarding liquidity and its ability to meet financial obligations?

The company reported consolidated working capital of $1.62 billion at September 29, 2001, with substantial cash and short-term investment balances. Management believes that existing resources are sufficient to meet the working capital requirements of its continuing businesses for at least the next 24 months. Investments in property, plant, and equipment are expected to approximate $85-90 million for 2001.

TMO 10-Q Quarterly Report Q3 FY2001 — Revenue, Net Income, EPS

Summary

Thermo Fisher Scientific Inc. (TMO) reported its financial results for the period ending September 29, 2001. The company's revenues for the third quarter of 2001 were $512.9 million, a decrease from $546.9 million in the same period of 2000. This decline was attributed to an 8% revenue decrease in the Optical Technologies segment and a 4% decrease in the Measurement and Control segment, impacted by ongoing market downturns in telecommunications and semiconductor industries, as well as divestitures. The company incurred significant restructuring and other unusual costs, particularly in the second and third quarters of 2001, totaling $9.6 million in Q3 2001, impacting operating income. Despite revenue pressures and restructuring charges, the Life Sciences segment showed growth in sales, driven by demand for clinical diagnostic and mass spectrometry products. The company also reported progress on its discontinued operations, including the sale of its power generation business and the planned spinoff of Viasys Healthcare.

Key Highlights

1Third quarter 2001 revenues decreased by 6.2% to $512.9 million compared to $546.9 million in the prior year's third quarter, primarily driven by declines in the Optical Technologies and Measurement & Control segments.
2Operating income significantly decreased to $28.6 million from $109.5 million year-over-year, largely due to $9.6 million in restructuring and other unusual costs incurred in Q3 2001.
3The Life Sciences segment demonstrated resilience with a sales increase of 5.6% to $200.6 million, driven by strong demand for clinical diagnostic and mass spectrometry equipment.
4Significant restructuring charges totaling $9.6 million were recognized in Q3 2001, impacting profitability, with further evaluation of additional restructuring actions underway.
5The company made progress in divesting non-core assets, including the sale of its power generation business components and specific units within the Measurement and Control segment.
6The company announced plans to spin off its Viasys Healthcare Inc. subsidiary, expected to reduce net assets of discontinued operations and retained earnings by approximately $300 million.
7Diluted earnings per share from continuing operations were $0.14 for Q3 2001, down from $0.04 in Q3 2000 (although the prior year figure appears unusually low and may warrant further investigation with the full filing).

THERMO FISHER SCIENTIFIC INC. Quarterly Report for Q3 Ended Sep 29, 2001

Summary

Key Highlights

Frequently Asked Questions